Skip to main content
SpringerLink
Log in

Heart diseases and stroke

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

A heterogeneous group of heart diseases, varying by cardiac anatomy and physiology, are responsible for a variety of embolic materials that result in cerebral and systemic embolism. Atrial fibrillation accounts for nearly half of all cardioembolic stroke, particularly in the elderly, but in the young congenital septal abnormalities such as patent foramen ovale play a more important role. Therapeutic strategies include stabilization or treatment of the underlying heart disease and prevention of embolism. Oral anticoagulant therapy is indicated for many but decision making on balancing the benefits versus risks can be difficult. New endovascular therapies and devices have become available and await clinical trials that allow them to be compared with existing medical therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Foulkes MA, Wolf PA, Price TR, et al.: The Stroke Data Bank: design, methods and baseline characteristics. Stroke 1988, 19:547–554.

    PubMed  CAS  Google Scholar 

  2. Bogousslavsky J, Cachin C, Regli F, et al.: Cardiac sources of embolism and cerebral infarction, clinical consequences and vascular concomitants. Neurology 1991, 41:855–859.

    PubMed  CAS  Google Scholar 

  3. Roquer J, Campello AR, Gomis M: Sex differences in first-ever acute stroke. Stroke 2003, 34:1581–1585.

    Article  PubMed  Google Scholar 

  4. Kittner SJ, Stern BJ, Wozniak M, et al.: Cerebral infarction in young adults: the Baltimore-Washington Cooperative Young Stroke Study. Neurology 1998, 50:890–894.

    PubMed  CAS  Google Scholar 

  5. Kolominsky-Rabas PL, Weber M, Gefeller O, et al.: Epidemiology of ischemic stroke subtypes according to TOAST criteria. Stroke 2001, 32:2735–0.

    Article  PubMed  CAS  Google Scholar 

  6. Broderick JP, Phillips SJ, O’Fallon WM, et al.: Relationship of cardiac disease to stroke occurrence, recurrence and mortality. Stroke 1992, 23:1250–1256.

    PubMed  CAS  Google Scholar 

  7. Gage BF, Waterman AD, Shannon W, et al.: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864–2870.

    Article  PubMed  CAS  Google Scholar 

  8. Albers GW, Sherman DG, Gress DR, et al.: Stroke prevention in nonvalvular atrial fibrillation; a review of prospective randomized trials. Ann Neurol 1991, 30:511–518.

    Article  PubMed  CAS  Google Scholar 

  9. Singer DE, Albers GW, Dalen JE, et al.: Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:429–456.

    Article  Google Scholar 

  10. Quality Standard Committee of the American Academy of Neurology: Practice Parameter: Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation. Neurology 1998, 51:671–673.

    Google Scholar 

  11. Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 2001, 38:1231–1266.

    Article  PubMed  CAS  Google Scholar 

  12. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825–1833.

    Article  Google Scholar 

  13. Sherman DG, Kim SG, Boop BS, et al.: Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management AFFIRM study. Arch Int Med 2005, 165:1185–1191. An analysis of stroke occurring in the AFFIRM trial, which reinforces the benefits of anticoagulation even when it appears that sinus rhythm has been restored.

    Article  Google Scholar 

  14. Deplanque D, Corea F, Arquizan C, et al.: Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? SAFE I Study Investigators. Heart 1999, 82:563–569.

    PubMed  CAS  Google Scholar 

  15. Joint Commission on Accreditation of Healthcare Organizations: Standardized Stroke Measure Set. http://www.jcaho.org/dscc/dsc/performance+measures/ stroke+measure+set.htm. Accessed September 15, 2005.

  16. SPORTIF Executive Steering Committee for the SPORTIF V Investigators: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005, 293:690–698.

    Article  Google Scholar 

  17. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996, 348:633–638.

    Article  Google Scholar 

  18. Hughes S: One arm of ACTIVE trial stopped as warfarin shows superior outcomes to clopidogrel plus aspirin in AF. Heartwire September 7, 2005. http://www.theheart.org.

  19. Hohnloser SH, Connolly SJ: Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. J Cardiovasc Electrophysiol 2003, 14:S60-S63.

    Article  PubMed  Google Scholar 

  20. Ostermayer SH, Reisman M, Kramer PH, et al.: Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation. J Am Coll Cardiol 2005, 46:9–14.

    Article  PubMed  Google Scholar 

  21. http://www.atritech.net

  22. Cappato R, Calkins H, Chen SA, et al.: Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005, 111:1100–1105.

    Article  PubMed  Google Scholar 

  23. Tong DC, Bolger A, Albers GW: Incidence of transcranial Doppler detected microemboli in patients referred for echocardiography. Stroke 1994, 25:2138–2141.

    PubMed  CAS  Google Scholar 

  24. Hagen PT, Scholz DG, Edwards WD: Incidence and size of patent foramen ovale during the first 10 decades of life. Mayo Clin Proc 1984, 59:17–20.

    PubMed  CAS  Google Scholar 

  25. Lechat P, Mas JL, Lascault G, et al.: Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988, 319:1148–1152.

    Article  Google Scholar 

  26. Lynch JJ, Shuchard GH, Gross CM, Wann LS: Prevalence of right-to-left atrial shunting in a healthy population; detection by Valsalva maneuver contrast echocardiography. Am J Cardiol 1984, 68:1478–1480.

    Article  Google Scholar 

  27. Louie EK, Konstadt SN, Rao TL, Scanlon PJ: Transesophageal echocardiographic diagnosis of right to left shunting across the foramen ovale in adults without prior stroke. Am J Coll Cardiol 1993, 21:1231–1237.

    Article  CAS  Google Scholar 

  28. Cabanes L, Mas JL, Cohen A, et al.: Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. Stroke 1993, 24:1865–1873.

    PubMed  CAS  Google Scholar 

  29. Homma S, Sacco RL, DiTullio MR, et al., for the PFO in Cryptogenic Stroke Study (PICSS) Investigators: Effect of medical treatment in stroke patients with patent foramen ovale. Circulation 2002, 105:2625–2631. A substudy of the pivotal WARSS trial, this represents the only randomized data on aspirin versus warfarin in patients with cryptogenic stroke and a patent foramen ovale.

    Article  PubMed  Google Scholar 

  30. Windecker S, Wahl A, Chatterjee T, et al.: Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 2000, 101:893–898.

    PubMed  CAS  Google Scholar 

  31. NMT Medical: ClosureI trial. http://www.nmtmedical.com/ products/ci/pfo/index.htm. Accessed September 15, 2005.

  32. Amplatzer Medical Professionals: RESPECT PFO trial. http://www.amplatzer.com/us/medical_professionals/ respect_trial.html. Accessed September 15, 2005.

  33. Cardia Inc: Cardia family of products. http://www. cardiainc.com/. Accessed September 15, 2005.

  34. Maisel L: Patent foramen ovale closure devices: moving beyond equipoise. JAMA 2005, 294:366–369.

    Article  PubMed  CAS  Google Scholar 

  35. Messé SR, Cucchiara B, Luciano J, et al.: PFO management: meurologists vs cardiologists. Neurology 2005, 65:172–173.

    Article  PubMed  Google Scholar 

  36. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ: Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997, 29:1074–108. Erratum in J Am Coll Cardiol 1998, 32:555.

    Article  PubMed  CAS  Google Scholar 

  37. Massie BM, Krol WF, Ammon SE, et al.: The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004, 10:101–112.

    Article  PubMed  CAS  Google Scholar 

  38. http://www.clinicaltrials.gov/ct/gui/show/NCT00041938

  39. Baddour LM, Wilson WR, Bayer AS, et al.: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation 2005, 111:3167–3184. This article is an extensive and recent review of infective endocarditis. This is an important resource for a less frequently encountered cause for stroke where management decisions can be difficult.

    Article  Google Scholar 

  40. Chapot R, Houdart E, Saint-Maurice JP, et al.: Endovascular treatment of cerebral mycotic aneurysms. Radiology 2002, 222:389–396.

    Article  PubMed  Google Scholar 

  41. The French Study of Aortic Plaques in Stroke Group: Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 1996, 334:1216–1221.

    Article  Google Scholar 

  42. Donnan GA, Davis SM, Jones EF, et al.: Aortic source of brain embolism. Curr Treat Options Cardiovasc Med 2003, 5:211–219.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cerebrovascular Center, Section of Stroke & Neurologic Intensive Care, Cleveland Clinic, 9500 Euclid Avenue, S-91, 44195, Cleveland, OH, USA

    Cathy A. Sila MD

Authors
  1. Cathy A. Sila MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cathy A. Sila MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sila, C.A. Heart diseases and stroke. Curr Neurol Neurosci Rep 6, 23–27 (2006). https://doi.org/10.1007/s11910-996-0005-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-996-0005-z

Keywords

Search

Navigation